Thymopentin (TP-5)
Synthetic pentapeptide (Arg-Lys-Asp-Val-Tyr) corresponding to the active site of thymopoietin. Modulates T-lymphocyte differentiation + function. Approved in some EU + Asian markets for rheumatoid arthritis + immunodeficiency.
How it clearsHalf cleared in ~1.5h. Most (~96%) gone by ~7.5h.
Compare these compounds
Mechanism, evidence, legal path, cost — all side-by-side.
Older immunomodulator (1980s development) — Italfarmaco's Timunox brand was approved in Italy + several other markets for primary immunodeficiency + rheumatoid arthritis adjunct. Mechanism is well-characterized (T-cell differentiation marker upregulation) but the magnitude of clinical effect in autoimmune use was modest, and adoption was overtaken by biologics + DMARDs. Russian + Chinese protocol literature uses TP-5 in chronic-viral + post-chemo immune-restoration contexts. Distinct from Thymosin α-1 (Stack catalogs both — different sequences, overlapping but not identical immune effects).
Older compound — clinical adoption faded as biologics + DMARDs took over autoimmune indications. Italian Italfarmaco product (Timunox) is the verified-quality source; non-EU grey-market product is variable. Don't conflate with Thymosin α-1 or Thymalin.
Upload your data to see how it relates to Thymopentin.
Upload a lab file (LabCorp / Quest) or DNA file (23andMe / AncestryDNA). Stack will show your specific markers alongside the literature-reported response windows.
Upload in /historyPer-claim grading. Each claim is graded independently — same peptide, different claims can carry different grades.
- CLimited evidence
Thymopentin (TP-5) — primary mechanism: synthetic pentapeptide (arg-lys-asp-val-tyr) corresponding to the active site of thymopoietin. modulates t-lymphocyte differentiation + function. approved in some eu + asian markets for rheumatoid arthritis + immunodeficiency.
1 supporting referencesVerified 13d ago
External links to PubMed searches, ClinicalTrials.gov, and FDA materials. We do not host papers — we point at canonical sources.
Approved in Italy + several EU/Asian markets (Timunox) · research-grey in US
Pre-filled with this compound's published dose range: 1-50 mg subcutaneous (regimen-dependent) · 3× weekly or daily course, subcutaneous
Draw volume exceeds 100 units (1 mL). Either reduce dose or split into multiple injections.
Calculator is a discussion tool. Verify reconstitution + dosing with a qualified provider. Stack is not a prescription source. Use sterile technique and inspect every vial.
No field reports yet
Field reports are added as users share their real-world protocols.
Next visit & citations
Handoff & sources
Running this compound? Log it in /history, then open Dr Passport before your visit. Methodology explains grades; the research dashboard sorts the full catalog with citations.